Risk Stratification of Nodal PTCL

Multicenter Study to Assess the Prognostic Significances of NCCN-IPI and Post-treatment PET Results in Patients With Newly Diagnosed Nodal PTCL

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03040206

Enrollment

405

Registered

2017-02-02

Start date

2017-01-31

Completion date

2017-12-31

Last updated

2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified

Brief summary

This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish a risk stratification model for nodal PTCL patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients diagnosed with nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma \[ALCL\], anaplastic lymphoma kinase \[ALK\]-negative) * Patients diagnosed with between January 1, 2004 and April 30, 2016 * initially treated with curative intent * Patients with standard 18F-fluorodeoxyglucose (FDG) PET or PET-CT data at the time of diagnosis and at the end of primary treatment

Exclusion criteria

* Patients diagnosed with extranodal PTCLs, including followings (extranodal NK/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; EBV-positive T-cell lymphoproliferative childhood disorders, and primary cutaneous lymphomas) * Patients with ALCL-ALK+ * Patients who do not have 18F-FDG PET or PET-CT data either at diagnosis or at the end of treatment available for review

Design outcomes

Primary

Measure	Time frame	Description
progression-free survival	5 year	Time between the date of diagnosis and any kinds of death or disease relapse/progrression

Secondary

Measure	Time frame	Description
overall survival	5 year	Time between the date of diagnosis and any kinds of death

Countries

South Korea

Outcome results